Evidence map›Paper›PMID 36381329›Full record

ArticleAmerican journal of cancer research2022

High miR-99b expression is associated with cell proliferation and worse patient outcomes in breast cancer.

Masanori Oshi, Yoshihisa Tokumaru, Matthew Gk Benesch, Nobuhiko Sugito, Rongrong Wu, Li Yan, Akimitsu Yamada, Takashi Chishima, Takashi Ishikawa, Itaru Endo and 1 more

Open access · greenAbstract read
In one paragraph

Article in American journal of cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. HighAmerican journal of cancer research · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Masanori OshiDepartment of Surgical Oncology, Roswell Park Comprehensive Cancer Center Buffalo 14263, New York, USA.
Yoshihisa TokumaruDepartment of Surgical Oncology, Roswell Park Comprehensive Cancer Center Buffalo 14263, New York, USA.
Matthew Gk BeneschDepartment of Surgical Oncology, Roswell Park Comprehensive Cancer Center Buffalo 14263, New York, USA.
Nobuhiko SugitoDepartment of Surgical Oncology, Graduate School of Medicine, Gifu University 1-1 Yanagido, Gifu 501-1194, Japan.
Rongrong WuDepartment of Surgical Oncology, Roswell Park Comprehensive Cancer Center Buffalo 14263, New York, USA.
Li YanDepartment of Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center Buffalo 14263, New York, USA.
Akimitsu YamadaDepartment of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine Yokohama 236-0004, Japan.
Takashi ChishimaDepartment of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine Yokohama 236-0004, Japan.
Takashi IshikawaDepartment of Breast Surgery and Oncology, Tokyo Medical University Tokyo 160-8402, Japan.
Itaru EndoDepartment of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine Yokohama 236-0004, Japan.
Kazuaki TakabeDepartment of Surgical Oncology, Roswell Park Comprehensive Cancer Center Buffalo 14263, New York, USA.
Roswell Park Comprehensive Cancer Center · USYokohama City University · JPTokyo Medical University · JP

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI CANDACE S JOHNSON · 1985 to 2026
$116.6M
Impact of Circulating Myeloid Cell Clusters on Anti-Tumor ImmunityR01CA250412 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI ABRAMS, SCOTT I., EVANS, SHARON S · 2021 to 2025
$3.4M
Functional Significance of individual p53 mutations in determining the role of estrogen receptor beta in triple negative breast cancerR01CA251545 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI DAS, GOKUL M. · 2021 to 2025
$2.9M
Leveraging the GTP Biosynthetic Pathway for Anti-Tumor TherapiesR37CA248018 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Anna Bianchi-Smiraglia · 2021 to 2026
$2.3M
Multiparametric photoacoustic and ultrasonic imaging of the breast in cranial-caudal viewR01EB029596 · NIBIB · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI XIA, JUN · 2020 to 2023
$1.4M
NCI NIH HHS P30 CA016056NCI NIH HHS R01 CA250412NCI NIH HHS R01 CA251545NCI NIH HHS R37 CA248018NIBIB NIH HHS R01 EB029596
6 · The paper itself

Abstract

Although miR-99b is a known suppressive microRNA (miRNA) in several cancers, its role in breast cancer has not been elucidated. In this study, we examined the clinical relevance of miR-99b expression in breast cancer. We analyzed miRNA and mRNA expression and their relationships with clinical parameters in 1,961 breast cancer samples from two independent large cohorts, the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) and The Cancer Genome Atlas (TCGA). Several algorithms, including gene set enrichment analysis (GSEA) and xCell, have been used to investigate biological functions and the tumor microenvironment. High miR-99b expression significantly enriched the mTORC1 signaling gene set in breast cancer (NES = 1.63, FDR = 0.03, and NES = 1.58, FDR = 0.10, in METABRIC and TCGA, respectively). No other mechanisms, including the epithelial mesenchymal transition, NFκB, and TGF-β signaling, were consistently enriched in both cohorts. MiR-99b-high breast cancer was associated with high homologous recombination deficiencies, intratumor heterogeneity, and high rates of mutation and neoantigens. In agreement, miR-99b-high breast cancer was associated with increased cell proliferation, correlating with Nottingham histological grade, and significant enrichment of E2F targets, G2/M checkpoint, and mitotic spindle gene sets consistently in both cohorts (

Indexed as

biomarkerbreast cancerCell proliferationgene expressionmicroRNAsignalingsurvivaltumor microenvironment

Identifiers

PMID36381329
PMCPMC9641402
OpenAlexW4292103700

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.